Although five ALK tyrosine kinase inhibitors (TKIs) have been approved for the treatment of ALK-positive non-small cell lung cancer, the sensitivity of these newly discovered rare ALK fusion variants to ALK TKIs remains unclear. Here, ALK is linked to non-small cell lung carcinoma.